Clinical Trials
74 trialsEndoxifen in Adults With Hormone Receptor Positive Solid Tumors
National Institutes of Health Clinical Center (CC)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903
Risen (Suzhou) Pharma Tech Co., Ltd.
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Tempest Therapeutics
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Sutro Biopharma, Inc.
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
AstraZeneca
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
M.D. Anderson Cancer Center
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Exelixis
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Inspirna, Inc.
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Compugen Ltd
MK-3475 Immunotherapy in Endometrial Carcinoma
Washington University School of Medicine
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Acepodia Biotech, Inc.
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
DUET-3
Xencor, Inc.
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Prelude Therapeutics
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Arcus Biosciences, Inc.
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
Development of a New Early Detection Test to Reduce Racial Disparities in Endometrial Cancer (EC) Death Rates
Mayo Clinic
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer
Endocyte
DUET-4
Xencor, Inc.
DUET-2
Xencor, Inc.
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
Ohio State University Comprehensive Cancer Center
NP137
Centre Leon Berard
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
Incyte Corporation
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
MacroGenics
PROLOG
The Netherlands Cancer Institute
Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy
Stanford University
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
Eisai Inc.
Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers
Memorial Sloan Kettering Cancer Center
AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies
Dana-Farber Cancer Institute
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
Novartis
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Abramson Cancer Center at Penn Medicine
Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers
National Institutes of Health Clinical Center (CC)
IOSI-NDU-001
Oncology Institute of Southern Switzerland
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Dana-Farber Cancer Institute
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer
Masonic Cancer Center, University of Minnesota
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
GlaxoSmithKline
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
GlaxoSmithKline
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids
H. Lee Moffitt Cancer Center and Research Institute
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery
University of Miami
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Merrimack Pharmaceuticals
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Alliance for Clinical Trials in Oncology
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
University of Southern California
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Regeneron Pharmaceuticals
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Regeneron Pharmaceuticals
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
BIND Therapeutics
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Rutgers, The State University of New Jersey
Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients
Washington University School of Medicine